Swiftwater , Pennsylvania ( CNN ) -- Vaccine manufacturing giant Sanofi Pasteur opened its doors to the media Wednesday , inviting reporters to a first-of-its-kind , up-close look at its H1N1 flu vaccine production facility . Sanofi , the only manufacturer licensed to make H1N1 vaccine in the United States , also released its final clinical trial data , a 42-day follow-up of its adult and pediatric trials . According to this latest data , a single dose of H1N1 vaccine induces a strong immune response in adults , but two doses will be needed for children 6 months to 9 years of age . `` These are extremely important data , '' said Wayne Pisano , president and CEO of Sanofi Pasteur , `` because they once again make clear not only the immunogenicity of Influenza A [ H1N1 ] 2009 Monovalent Vaccine manufactured by Sanofi Pasteur , but also the fact that this vaccine has a safety profile similar to that observed with seasonal influenza vaccine in all age groups studied . '' According to Sanofi , there were no serious adverse incidents associated with vaccination . While no cameras were allowed inside the production facility during the tour , journalists were taken through the bulk influenza vaccine manufacturing facility , where the virus is injected into eggs to produce vaccine ; the quality contol and sterility lab , where safety testing is done ; and the formulation and filling facility , where single dose syringes and multidose vials are filled . In response to questions about criticisms over a shortage of vaccine , Chris Viehbacher , CEO of parent company Sanofi Aventis , said he has 2,000 employees on-site 24 hours a day , seven days a week . Viehbacher said the facility is producing 5 million doses a week , and that will increase to between 9 million and 10 million by early December . By the end of this week , Sanofi will have shipped 20 million doses of H1N1 vaccine , according to the company . According to Viehbacher , Sanofi will be on target to ship the entire 75 million doses ordered by the U.S. Department of Health and Human Services by the end of the year . `` We are all working as fast as we can , '' Viehbacher said . `` Everyone would like to have more vaccine now but we have what we have . Those not at risk should have some degree of patience . '' Sanofi also will deliver 50 million doses of seasonal flu vaccine before the end of the month , the company said . By the end of the year , `` 125 million doses of both vaccines [ seasonal and H1N1 ] will be out the door , '' Viehbacher said . He added that it is important to understand that 85 percent of the manufacturing process is testing and quality control , not growing the vaccine . Sanofi , the largest vaccine company in the world , makes more than 45 percent of the flu vaccine distributed in the United States and about 40 percent of the world 's supply .
Journalists given tour of vaccine manufacturing area . Company says latest trials indicate children will need two doses of vaccine . Score: 6